EVLO Stock Overview
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Evelo Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.05 |
| 52 Week High | US$13.93 |
| 52 Week Low | US$0.028 |
| Beta | 2.03 |
| 1 Month Change | -12.74% |
| 3 Month Change | -9.17% |
| 1 Year Change | -98.44% |
| 3 Year Change | -99.98% |
| 5 Year Change | -99.97% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Is Evelo Biosciences (NASDAQ:EVLO) Using Debt In A Risky Way?
Aug 18
Evelo Biosciences GAAP EPS of -$0.40 beats by $0.03
Aug 11Marella Thorell is the new finance chief of Evelo Biosciences
Jul 18Evelo Biosciences: Hope After Dilution?
Jun 06Evelo Biosciences (NASDAQ:EVLO) Has Debt But No Earnings; Should You Worry?
Mar 21Is Evelo Biosciences (NASDAQ:EVLO) Weighed On By Its Debt Load?
Sep 25What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry?
Mar 11Evelo Bio secures ~$67.5M capital raise
Jan 29Evelo Biosciences expands EDP1815 mid-stage trial to atopic dermatitis
Jan 07Trade Alert: The Independent Chairman Of Evelo Biosciences, Inc. (NASDAQ:EVLO), David Epstein, Has Just Spent US$51k Buying 77% More Shares
Dec 15
Do Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?
Dec 11Evelo Biosciences identifies new lead oncology candidate
Dec 09Evelo Bio's EDP1815 completes enrollment targeting interim data in mid-stage psoriasis study
Dec 03Evelo Biosciences EPS beats by $0.04
Oct 29Shareholder Returns
| EVLO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 22.0% | -4.7% | -3.7% |
| 1Y | -98.4% | -2.7% | 20.2% |
Return vs Industry: EVLO underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: EVLO underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| EVLO volatility | |
|---|---|
| EVLO Average Weekly Movement | 27.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EVLO's share price has been volatile over the past 3 months.
Volatility Over Time: EVLO's weekly volatility has decreased from 39% to 28% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 66 | n/a | www.evelobio.com |
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology.
Evelo Biosciences, Inc. Fundamentals Summary
| EVLO fundamental statistics | |
|---|---|
| Market cap | US$949.14k |
| Earnings (TTM) | -US$82.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs EVLO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVLO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$82.35m |
| Earnings | -US$82.35m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -127.1% |
How did EVLO perform over the long term?
See historical performance and comparison